arrow
B

Barbara Willekens

antwerp university hospital
H指数:25
被引数:4,264

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Predicting disease progression in multiple sclerosis with clinically accessible information and technology

利用临床可获取的信息和技术预测多发性硬化症的疾病进展

2026-04-190
OAAI
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

在高危和低危侵袭性多发性硬化患者中保留神经功能:一项观察性队列研究

2026-04-040
OAAI
Corrigendum to “Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study” [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885]

勘误:“Ocrelizumab在复发型多发性硬化中的真实世界有效性:一项MSBase注册登记研究的子研究”[多发性硬化及相关疾病 第106卷;2026年2月;文章编号106885]

2026-03-170
PRE
Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis

步态步长测量作为多发性硬化可步行患者残疾进展的早期敏感标志物

2026-03-120
OAAI
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

迟发性对多发性硬化表型和结局的影响:多国注册研究的证据

2026-02-040
PRE
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI
Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease-Modifying Treatments for Multiple Sclerosis

靶向髓鞘再生的干预措施最新进展及对获批多发性硬化疾病修正疗法髓鞘再生效应的系统综述

2025-11-110
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Need for awareness and surveillance of long-term post-COVID neurodegenerative disorders. A position paper from the neuroCOVID-19 task force of the European Academy of Neurology

对长期新冠病毒感染后神经退行性疾病的认知与监测需求。欧洲神经科学学会neuroCOVID-19工作组立场文件

2025-05-060
OA
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study

血清阴性NMOSD的进展独立于复发活动和复发相关的恶化:一项国际队列研究

2025-04-140
OA
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
2024-11-012
OAAI
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
2024-09-040
PRE